3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
4
Neoplasms
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
48
Methotrexate
33
Cytarabine
27
fludarabine
23
fludarabine phosphate
22
Rituximab
22
Filgrastim
21
Vincristine
19
Busulfan
19
Whole-Body Irradiation
18
Mycophenolic Acid
18
Dexamethasone
18
Antilymphocyte Serum
17
Cyclosporine
16
Etoposide
15
Tacrolimus
14
Melphalan
14
Calcium Dobesilate
14
pegaspargase
12
Peripheral Blood Stem Cell Transplantation
12
Doxorubicin
12
Radiotherapy
11
Clofarabine
11
Granulocyte Colony-Stimulating Factor
10
Thiotepa
9
Bortezomib
9
thymoglobulin
8
Dasatinib
8
Asparaginase
8
plerixafor
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
isatuximab
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts